Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)

NCT02670707 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT02670707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)
Lead sponsor
Baylor College of Medicine
Phase
Phase 3
Overall status
Recruiting
Start date
March 7, 2016
Completion date
January 31, 2029
Enrollment
124 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis